ArticleACS omega2025
Penetration of the Blood-Brain Barrier and Liver for Repairing Motor Disorders in a Rat Model of Parkinson's Disease Using a Nanocopolymer.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder that results in dopamine deficiency and motor symptoms. The blood-brain barrier (BBB) poses a significant challenge in delivering therapeutics to the central nervous system (CNS). In this study, a new nanocopolymer was developed to penetrate the BBB and deliver dopamine to the substantia nigra pars compacta (SNpc) in a Parkinson's-induced rat model. The dopamine loading was 85%, with a release efficiency of 75%. Subsequently, 70 Swiss rats were induced to have Parkinson's using 6-OHD. After 3 days of administration, Parkinson's symptoms emerged and were confirmed by specialists. The induced animals were divided into subgroups based on the dosage of the nanocopolymer (10, 20, or 40 mg for 14 days), after which they were dissected. The brains were sectioned, and the nanocopolymer's penetration was observed and imaged with fluorescence microscopy. Results showed that the nanocopolymer successfully crossed the BBB and the capillary endothelium in the striatum and substantia nigra. Presence of dopamine in the striatum was confirmed by the presence of yellow-green fluorescence in the substantia nigra. Reduced dopamine autoxidation provides sustained delivery of dopamine to the brain. The results also demonstrated the efficacy of this nanocopolymer in penetrating the rat liver, where it affected liver cells significantly more than it did in the brain. The developed nanocopolymer effectively crossed the BBB and elevated dopamine levels in the brain, alleviating motor symptoms in a rat model as an early-stage treatment for Parkinson's disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.